Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TGTX | TG Therapeutics, Inc.

IndexRUT P/E- EPS (ttm)-1.27 Insider Own1.10% Shs Outstand141.50M Perf Week-9.86%
Market Cap1.39B Forward P/E182.80 EPS next Y0.05 Insider Trans-0.51% Shs Float138.05M Perf Month-13.20%
Income-175.70M PEG- EPS next Q0.13 Inst Own69.70% Short Float / Ratio20.26% / 5.71 Perf Quarter-61.27%
Sales24.10M P/S57.54 EPS this Y44.40% Inst Trans-5.86% Short Interest27.97M Perf Half Y-38.70%
Book/sh0.29 P/B31.52 EPS next Y106.80% ROA-84.70% Target Price28.94 Perf Year45.31%
Cash/sh0.95 P/C9.57 EPS next 5Y- ROE-309.60% 52W Range4.86 - 35.67 Perf YTD-22.74%
Dividend- P/FCF- EPS past 5Y5.20% ROI-148.70% 52W High-74.38% Beta2.09
Dividend %- Quick Ratio2.50 Sales past 5Y78.80% Gross Margin88.50% 52W Low88.07% ATR0.61
Employees244 Current Ratio2.90 Sales Q/Q2606.10% Oper. Margin- RSI (14)28.95 Volatility4.64% 4.74%
OptionableYes Debt/Eq2.41 EPS Q/Q-11.90% Profit Margin- Rel Volume0.52 Prev Close9.25
ShortableYes LT Debt/Eq2.41 EarningsAug 01 BMO Payout- Avg Volume4.89M Price9.14
Recom2.10 SMA20-11.30% SMA50-30.15% SMA200-48.26% Volume2,542,256 Change-1.19%
Date Action Analyst Rating Change Price Target Change
Aug-02-23Upgrade Goldman Sell → Neutral $16 → $12
Jun-26-23Resumed Jefferies Buy $55 → $40
May-20-22Initiated BofA Securities Underperform $5
Feb-23-22Reiterated B. Riley Securities Buy $49 → $35
Nov-15-21Downgrade Goldman Neutral → Sell $33 → $26
Apr-20-21Initiated Goldman Neutral $50
Apr-19-21Reiterated H.C. Wainwright Buy $79 → $89
Sep-01-20Initiated JP Morgan Overweight $38
Aug-11-20Reiterated H.C. Wainwright Buy $32 → $38
Jun-05-20Initiated Evercore ISI Outperform $60
Sep-22-23 07:30AM
Sep-07-23 07:30AM
Sep-06-23 01:06PM
Aug-29-23 12:43AM
Aug-19-23 11:22AM
11:05AM Loading…
Aug-12-23 11:05AM
Aug-04-23 06:20AM
Aug-03-23 06:10AM
Aug-01-23 04:04PM
08:30AM Loading…
Jul-31-23 08:30AM
Jul-25-23 11:46AM
Jul-24-23 09:35AM
Jul-21-23 12:30PM
Jul-13-23 04:05PM
Jul-10-23 02:01AM
Jul-03-23 09:00AM
Jul-01-23 09:00AM
Jun-27-23 09:22AM
Jun-08-23 08:30AM
Jun-06-23 01:13PM
Jun-05-23 07:30AM
Jun-02-23 09:15AM
09:15AM Loading…
Jun-01-23 09:15AM
May-31-23 07:30AM
May-18-23 11:05AM
May-04-23 10:16AM
May-01-23 10:32PM
Apr-28-23 04:30PM
Apr-27-23 07:30AM
Apr-25-23 08:45AM
Apr-13-23 03:49PM
Apr-11-23 04:07PM
Apr-06-23 06:15PM
Mar-31-23 07:30AM
Mar-30-23 06:15PM
Mar-28-23 09:07AM
Mar-24-23 06:00PM
Mar-15-23 06:00PM
Mar-09-23 09:19AM
Mar-03-23 08:30AM
Feb-28-23 09:05AM
Feb-24-23 07:30AM
Feb-15-23 06:00PM
Feb-14-23 07:30AM
Feb-07-23 06:00PM
Jan-30-23 06:00PM
Jan-26-23 07:00AM
Jan-18-23 07:22AM
Jan-12-23 06:00PM
Jan-09-23 12:00PM
Jan-06-23 07:30AM
Dec-30-22 05:27PM
Dec-29-22 02:47PM
Dec-28-22 06:35PM
Dec-08-22 09:35PM
Dec-02-22 09:55AM
Nov-24-22 06:49AM
Nov-21-22 08:48AM
Nov-16-22 12:00PM
Nov-12-22 07:43AM
Nov-11-22 07:48PM
Nov-10-22 05:04PM
Nov-08-22 07:30AM
Oct-26-22 07:30AM
Oct-19-22 08:55AM
Oct-13-22 07:30AM
Sep-11-22 07:00AM
Sep-09-22 07:30AM
Aug-29-22 09:55AM
Aug-25-22 12:32PM
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WEISS MICHAEL SCEO and PresidentAug 11Buy10.13100,0001,013,00012,073,021Aug 14 09:54 AM
Lonial SagarDirectorJun 23Sale23.3734,854814,53893,878Jun 26 05:00 PM
Power Sean AChief Financial OfficerJun 02Sale26.7073,6471,966,375654,836Jun 05 06:26 PM
Echelard YannDirectorJan 06Buy10.649,00095,760201,848Jan 06 05:01 PM
Charney Laurence NDirectorJan 04Sale11.1030,000333,000234,729Jan 06 05:00 PM